

| DOCUMENT NUMBER: | |
|------------------|-------------------|
| DOCUMENT TITLE: | |
| DOCUMENT NOTES: | |
| | |
| | |
| LOCATION: | VERSION: |
| DOC TYPE: | STATUS: |
| | |
| EFFECTIVE DATE: | NEXT REVIEW DATE: |
| RELEASE DATE: | EXPIRATION DATE: |
| | |
| AUTHOR: | PREVIOUS NUMBER: |
| OWNER: | CHANGE NUMBER: |

WAM Change Management Process

Purpose

This process describes the workflow for evaluation, approval, and implementation of proposed changes to the Sysmex WAM rules for the KP Southern California (SCAL) laboratories.

Policy

- When there is a proposal for a change to the WAM middleware autoverification system, an evaluation will be done by the stakeholders.
- The evaluation shall consist of testing the change, and communicating the assessment to the Hematology UA Working Group (HUWG) prior to putting it in production.
- New rules implemented will be included in the annual validation of rules.

Process for WAM Change

The process for any WAM change will involve proposal, evaluation, testing, assessment, and implementation. Refer to the steps below on the entire process.

| Stage | Description | | |
|-------|--|--|--|
| 1 | The representative shall present the proposal utilizing the SBAR | | |
| 2 | tool. Ifseventy percent majority of HUWG approved the proposal, | then The decision is captured. A Sysmex Change Request Form (CRF) will be submitted to the Sysmex Technical | |
| | | Assistance Center (TAC). Co-chair/s of HUWG will submit on behalf of the group. | |
| | proposal didn't obtain approval from the majority, | The decision is captured. No CRF will be submitted by the WG at the current time. The proposal can be revisited. | |
| | | | |

WAM Change Management Process, Continued

Process for WAM Change

Continuation

| Stage | Description | | |
|-------|--|--|--|
| 3 | Once the proposed change is in the Test environment, the change will be tested by at least two members of the WG. The testers shall include at least one medical center representative and a representative of the regional lab. | | |
| 4 | Testers will assess the results of the testing. If then | | |
| | the testing passed by achieving the desired result of the proposal, | The change will be scheduled to move to Production. The scheduled date will be announced and shall be agreed upon by the WG. | |
| | the testing failed to achieve the desired result of the proposal, | The outcome will be shared with the WG to reconsider a new proposal or abandon by seeking an alternate workflow. | |
| 5 | Upon implementing the proposed change in Production, the laboratories shall document and validate the change with the proper approvals. | | |

WAM Change Management Process, Continued

Controlled Documents

The following controlled documents support this policy.

Locally approved versions will have different document numbers.

| Document Number | Title |
|------------------------|-------------------------|
| SCPMG-QMS-0025 | Autoverification Policy |

Non-Controlled Documents

The following non-controlled documents support this policy.

Sysmex WAM v5.x User Manual, Document Number 1036-MKT, Rev.3 August 2016

Author(s)

SCPMG Hematology Working Group – Sysmex Users Subgroup

Eleanor E. Callasan

Signature Manifest

Document Number: RIV-PPP-1139 Revision: 01

Title: WAM Change Management Process

Effective Date: 14 Nov 2023

All dates and times are in Pacific Standard Time.

WAM Change Management Process

Operations Director Approval

| Name/Signature | Title | Date | Meaning/Reason |
|----------------------------|--------------------------------|--------------------------|----------------|
| Annaleah Raymond (Q741709) | Laboratory Operations Director | 08 Nov 2023, 09:26:32 PM | Approved |

Medical Director Approval

| Name/Signature | Title | Date | Meaning/Reason |
|----------------------|---------------|--------------------------|----------------|
| Mark Taira (P161328) | CLIA Director | 08 Nov 2023, 10:12:08 PM | Approved |